Trial Profile

Phase I Study of Erbitux (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Irinotecan
Indications Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions
Sponsors Bristol-Myers Squibb

Most Recent Events

15 May 2008 Planned patient number changed from 60 to 48, reported by ClinicalTrials.gov.
15 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
11 Mar 2008 Status changed from recruiting to in progress.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com